Cardiovascular disease and thrombosis: Intersections with the immune system, inflammation, and the coagulation system.

IF 1 Q4 PHARMACOLOGY & PHARMACY Annales pharmaceutiques francaises Pub Date : 2024-08-17 DOI:10.1016/j.pharma.2024.08.005
Shivam Rajput, Rishabha Malviya, Saurabh Srivastava, Irfan Ahmad, Safia Obaidur Rab, Prerna Uniyal
{"title":"Cardiovascular disease and thrombosis: Intersections with the immune system, inflammation, and the coagulation system.","authors":"Shivam Rajput, Rishabha Malviya, Saurabh Srivastava, Irfan Ahmad, Safia Obaidur Rab, Prerna Uniyal","doi":"10.1016/j.pharma.2024.08.005","DOIUrl":null,"url":null,"abstract":"<p><p>The coagulation and immune system, both essential physiological systems in the human body, are intricately interconnected and play a critical role in determining the overall health of patients. These systems collaborate via various shared regulatory pathways, such as the Tissue Factor (TF) Pathway. Immunological cells that express TF and generate pro-inflammatory cytokines have the ability to affect coagulation. Conversely, coagulation factors and processes have a reciprocal effect on immunological responses by stimulating immune cells and regulating their functions. These interconnected pathways play a role in both preserving well-being and contributing to a range of pathological disorders. The close relationship between blood clotting and inflammation in the development of vascular disease has become a central focus of clinical study. This research specifically examines the crucial elements of this interaction within the contexts of cardiovascular disease and acute coronary syndrome. Tissue factor, the primary trigger of the extrinsic coagulation pathway, has a crucial function by inducing a proinflammatory reaction through the activation of coagulation factors. This, in turn, initiates coagulation and subsequent cellular signalling pathways. Protease-activated receptors establish the molecular connection between coagulation and inflammation by interacting with activated clotting factors II, X, and VII. Thrombosis, a condition characterised by the formation of blood clots, is the most dreaded consequence of cardiovascular disorders and a leading cause of death globally. Consequently, it poses a significant challenge to healthcare systems. Antithrombotic treatments efficiently target platelets and the coagulation cascade, but they come with the inherent danger of causing bleeding. Furthermore, antithrombotics are unable to fully eliminate thrombotic events, highlighting a treatment deficiency caused by a third mechanism that has not yet been sufficiently addressed, namely inflammation. Understanding these connections may aid in the development of novel approaches to mitigate the harmful mutual exacerbation of inflammation and coagulation. Gaining a comprehensive understanding of the intricate interaction among these systems is crucial for the management of diseases and the creation of efficacious remedies. Through the examination of these prevalent regulatory systems, we can discover novel therapeutic approaches that specifically target these complex illnesses. This paper provides a thorough examination of the reciprocal relationship between the coagulation and immune systems, emphasising its importance in maintaining health and understanding disease processes. This review examines the interplay between inflammation and thrombosis and its role in the development of thrombotic disorders.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales pharmaceutiques francaises","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.pharma.2024.08.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The coagulation and immune system, both essential physiological systems in the human body, are intricately interconnected and play a critical role in determining the overall health of patients. These systems collaborate via various shared regulatory pathways, such as the Tissue Factor (TF) Pathway. Immunological cells that express TF and generate pro-inflammatory cytokines have the ability to affect coagulation. Conversely, coagulation factors and processes have a reciprocal effect on immunological responses by stimulating immune cells and regulating their functions. These interconnected pathways play a role in both preserving well-being and contributing to a range of pathological disorders. The close relationship between blood clotting and inflammation in the development of vascular disease has become a central focus of clinical study. This research specifically examines the crucial elements of this interaction within the contexts of cardiovascular disease and acute coronary syndrome. Tissue factor, the primary trigger of the extrinsic coagulation pathway, has a crucial function by inducing a proinflammatory reaction through the activation of coagulation factors. This, in turn, initiates coagulation and subsequent cellular signalling pathways. Protease-activated receptors establish the molecular connection between coagulation and inflammation by interacting with activated clotting factors II, X, and VII. Thrombosis, a condition characterised by the formation of blood clots, is the most dreaded consequence of cardiovascular disorders and a leading cause of death globally. Consequently, it poses a significant challenge to healthcare systems. Antithrombotic treatments efficiently target platelets and the coagulation cascade, but they come with the inherent danger of causing bleeding. Furthermore, antithrombotics are unable to fully eliminate thrombotic events, highlighting a treatment deficiency caused by a third mechanism that has not yet been sufficiently addressed, namely inflammation. Understanding these connections may aid in the development of novel approaches to mitigate the harmful mutual exacerbation of inflammation and coagulation. Gaining a comprehensive understanding of the intricate interaction among these systems is crucial for the management of diseases and the creation of efficacious remedies. Through the examination of these prevalent regulatory systems, we can discover novel therapeutic approaches that specifically target these complex illnesses. This paper provides a thorough examination of the reciprocal relationship between the coagulation and immune systems, emphasising its importance in maintaining health and understanding disease processes. This review examines the interplay between inflammation and thrombosis and its role in the development of thrombotic disorders.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心血管疾病与血栓形成:与免疫系统、炎症和凝血系统的交集。
凝血系统和免疫系统都是人体重要的生理系统,它们之间有着错综复杂的联系,在决定患者整体健康方面发挥着至关重要的作用。这些系统通过组织因子(TF)途径等各种共享调控途径相互协作。表达 TF 并产生促炎细胞因子的免疫细胞能够影响凝血功能。相反,凝血因子和凝血过程通过刺激免疫细胞并调节其功能,对免疫反应产生相互影响。这些相互关联的途径既能维护人体健康,也能导致一系列病理紊乱。凝血和炎症在血管疾病发展过程中的密切关系已成为临床研究的核心重点。这项研究特别探讨了心血管疾病和急性冠状动脉综合征中这种相互作用的关键因素。组织因子是外凝血途径的主要触发因子,其关键作用是通过激活凝血因子诱发促炎反应。这反过来又启动了凝血和随后的细胞信号通路。蛋白酶活化受体通过与活化的凝血因子 II、X 和 VII 相互作用,建立了凝血与炎症之间的分子联系。血栓形成是心血管疾病最可怕的后果,也是全球死亡的主要原因。因此,它给医疗保健系统带来了巨大挑战。抗血栓治疗能有效地针对血小板和凝血级联反应,但也有引起出血的固有危险。此外,抗血栓药物无法完全消除血栓事件,这凸显了尚未充分解决的第三个机制(即炎症)造成的治疗缺陷。了解这些联系有助于开发新的方法,减轻炎症和凝血相互加重的危害。全面了解这些系统之间错综复杂的相互作用对于疾病的治疗和创造有效的疗法至关重要。通过研究这些普遍存在的调节系统,我们可以发现专门针对这些复杂疾病的新型治疗方法。本文深入探讨了凝血系统和免疫系统之间的相互关系,强调了它们在维持健康和了解疾病过程中的重要性。这篇综述探讨了炎症与血栓形成之间的相互作用及其在血栓性疾病发展中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Annales pharmaceutiques francaises
Annales pharmaceutiques francaises PHARMACOLOGY & PHARMACY-
CiteScore
1.70
自引率
7.70%
发文量
98
期刊介绍: This journal proposes a scientific information validated and indexed to be informed about the last research works in all the domains interesting the pharmacy. The original works, general reviews, the focusing, the brief notes, subjected by the best academics and the professionals, propose a synthetic approach of the last progress accomplished in the concerned sectors. The thematic Sessions and the – life of the Academy – resume the communications which, presented in front of the national Academy of pharmacy, are in the heart of the current events.
期刊最新文献
[Lipoprotein-associated phospholipase A2 (Lp-PLA2) : relevant biomarker and therapeutic target?] Editorial board Urinary cytomegalovirus excretion: The unresolved issues Trace level quantification of N-nitrosorasagiline in rasagiline tablets by LC-TQ-MS/MS A UPLC method development and validation study of Upadacitinib and its impurities in extended – release oral tablet dosage forms
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1